InsidersTradesSigma
Total declarations
Companies
▲ Purchases (30 ops.)
▼ Sales (0 ops.)
Insider track record
Board DirectorDisclosed buys
30
Disclosed sells
0
T+90 hit rate
63%
T+90 mean return
+2.9%
Across 16 buy signals with a settled T+90 return. Return basis: close on the day after publication.
Signal history
Explore the complete record of transactions filed by Titterton Lewis H jr, Director. Director active across 2 companies, notably Anixa Biosciences Inc. In total, 41 disclosures have been recorded. Split: 30 buys · 0 sell. Total volume traded: €905k. Activity tracked since 14 July 2021. The latest transaction was filed on 15 December 2025 (Levée d'options). Regulator: SEC (Form 4). All data is free.
Declarations41 total
2,836 sharesCommon StockSEC:0001493152-26-029030:0
Ideal exit: 13 Mar 2027 (T+270)
16,000 shares@ US$2.922.6% of flowCommon StockSEC:0001493152-25-027904:0
10,000 shares@ US$3.141.8% of flowCommon StockSEC:0001641172-25-019587:0
Ideal exit: 7 Apr 2026 (T+270)
1,699,844 shares@ US$0.1397.6% of flowCommon StockSEC:0001641172-25-009406:0
2,000 shares@ US$2.910.4% of flowCommon StockSEC:0001493152-25-003733:0
Ideal exit: 20 Oct 2025 (T+270)
2,000 shares@ US$3.010.4% of flowCommon StockSEC:0001493152-25-003330:0
Ideal exit: 19 Oct 2025 (T+270)
6,000 shares@ US$2.591.0% of flowCommon StockSEC:0001493152-25-003157:0
Ideal exit: 18 Oct 2025 (T+270)
10,000 shares@ US$2.571.6% of flowCommon StockSEC:0001493152-25-002717:0
Ideal exit: 14 Oct 2025 (T+270)
2,000,000 shares0Common StockSEC:0001437749-25-000657:0
16,000 shares@ US$2.5752.5% of flowCommon StockSEC:0001493152-24-042183:0
29,413 shares@ US$0.172.4% of flowCommon StockSEC:0001437749-24-030006:0
21,646 shares@ US$3.064.0% of flowCommon StockSEC:0001493152-24-029884:0
Ideal exit: 26 Apr 2025 (T+270)
796 shares@ US$2.810.1% of flowCommon StockSEC:0001493152-24-029354:0
Ideal exit: 21 Apr 2025 (T+270)
4,000 shares@ US$2.680.7% of flowCommon StockSEC:0001493152-24-024226:0
Ideal exit: 11 Mar 2025 (T+270)
405 shares@ US$2.700.1% of flowCommon StockSEC:0001493152-24-023802:0
Ideal exit: 10 Mar 2025 (T+270)
330 shares@ US$2.600.1% of flowCommon StockSEC:0001493152-24-023560:0
Ideal exit: 7 Mar 2025 (T+270)
10,738 shares@ US$2.521.6% of flowCommon StockSEC:0001493152-24-023295:0
Ideal exit: 4 Mar 2025 (T+270)
15,009 shares@ US$3.283.0% of flowCommon StockSEC:0001493152-24-014154:0
Ideal exit: 4 Jan 2025 (T+270)
16,000 shares@ US$2.5752.6% of flowCommon StockSEC:0001493152-23-036871:0
120,000 shares@ US$2.57518.5% of flowCommon StockSEC:0001493152-23-026127:0
40,000 shares@ US$2.5756.9% of flowCommon StockSEC:0001493152-22-027222:0
300,000 shares0Common StockSEC:0001493152-22-026101:0
30,000 shares@ US$2.5750.078% mcap9.7% of flowCommon StockSEC:0001493152-22-017926:0
16,000 shares@ US$2.5752.6% of flowCommon StockSEC:0001493152-22-017926:1
10,000 shares@ US$2.790.028% mcap3.5% of flowCommon StockSEC:0001493152-22-011291:0
Ideal exit: 21 Jan 2023 (T+270)
25 of 41 declarations
About Titterton Lewis H jr
Titterton Lewis H jr is an executive at Anixa Biosciences Inc.
